Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel.
Priyanka SharmaMiguel MartínJosé Angel García-SaenzQamar J KhanHenry L GómezAleix PratFernando MorenoYolanda Jerez-GilarranzAgusti BarnadasAntoni C PicornellMaría Del Monte-MillánMilagros González-RiveraTatiana MassarrahBeatriz Pelaez-LorenzoMaría Isabel PalomeroRicardo González Del ValJavier CortésHugo Fuentes-RiveraDenisse Bretel MoralesIván Márquez-RodasCharles M PerouCarolyn LehnYen Y WangJennifer R KlempJoshua V MammenJamie L WagnerAmanda L AminAnne P O'DeaJaimie HeldstabRoy A JensenBruce F KimlerAndrew K GodwinMiguel MartinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Neoadjuvant carboplatin plus docetaxel yields encouraging efficacy in TNBC. Patients achieving pCR or RCB I with this regimen demonstrate excellent 3-year RFS and OS without adjuvant anthracycline.